NASDAQ
RSLS

ReShape Lifesciences Inc

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

ReShape Lifesciences Inc Stock Price

Vitals

Today's Low:
$0.78
Today's High:
$0.8889
Open Price:
$0.8142
52W Low:
$0.78
52W High:
$22.4
Prev. Close:
$0.869
Volume:
103348

Company Statistics

Market Cap.:
$3.00 million
Book Value:
1.952
Revenue TTM:
$10.45 million
Operating Margin TTM:
-208.1%
Gross Profit TTM:
$6.80 million
Profit Margin:
0%
Return on Assets TTM:
-50.54%
Return on Equity TTM:
-178.05%

Company Profile

ReShape Lifesciences Inc had its IPO on 2007-11-15 under the ticker symbol RSLS.

The company operates in the Healthcare sector and Medical Devices industry. ReShape Lifesciences Inc has a staff strength of 40 employees.

Stock update

Shares of ReShape Lifesciences Inc opened at $0.81 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.78 - $0.89, and closed at $0.8.

This is a -7.94% slip from the previous day's closing price.

A total volume of 103,348 shares were traded at the close of the day’s session.

In the last one week, shares of ReShape Lifesciences Inc have slipped by -13.04%.

ReShape Lifesciences Inc's Key Ratios

ReShape Lifesciences Inc has a market cap of $3.00 million, indicating a price to book ratio of 0.1617 and a price to sales ratio of 0.3217.

In the last 12-months ReShape Lifesciences Inc’s revenue was $10.45 million with a gross profit of $6.80 million and an EBITDA of $-20589000. The EBITDA ratio measures ReShape Lifesciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ReShape Lifesciences Inc’s operating margin was -208.1% while its return on assets stood at -50.54% with a return of equity of -178.05%.

In Q2, ReShape Lifesciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.1%.

ReShape Lifesciences Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-63.42 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ReShape Lifesciences Inc’s profitability.

ReShape Lifesciences Inc stock is trading at a EV to sales ratio of 0.1381 and a EV to EBITDA ratio of 0.0414. Its price to sales ratio in the trailing 12-months stood at 0.3217.

ReShape Lifesciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$11.85 million
Total Liabilities
$4.40 million
Operating Cash Flow
$0
Capital Expenditure
$36000
Dividend Payout Ratio
0%

ReShape Lifesciences Inc ended 2024 with $11.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.85 million while shareholder equity stood at $6.74 million.

ReShape Lifesciences Inc ended 2024 with $0 in deferred long-term liabilities, $4.40 million in other current liabilities, 3000.00 in common stock, $-630342000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.57 million and cash and short-term investments were $4.57 million. The company’s total short-term debt was $109,000 while long-term debt stood at $0.

ReShape Lifesciences Inc’s total current assets stands at $10.54 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.04 million compared to accounts payable of $1.60 million and inventory worth $3.27 million.

In 2024, ReShape Lifesciences Inc's operating cash flow was $0 while its capital expenditure stood at $36000.

Comparatively, ReShape Lifesciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.8
52-Week High
$22.4
52-Week Low
$0.78
Analyst Target Price
$4

ReShape Lifesciences Inc stock is currently trading at $0.8 per share. It touched a 52-week high of $22.4 and a 52-week low of $22.4. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $1.26 and 200-day moving average was $3.73 The short ratio stood at 0.07 indicating a short percent outstanding of 0%.

Around 567.7% of the company’s stock are held by insiders while 574.9% are held by institutions.

Frequently Asked Questions About ReShape Lifesciences Inc

The stock symbol (also called stock or share ticker) of ReShape Lifesciences Inc is RSLS

The IPO of ReShape Lifesciences Inc took place on 2007-11-15

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$19.49
0.15
+0.78%
$110.34
-1.31
-1.17%
$180.9
-2.6
-1.42%
OM Infra Ltd (OMINFRAL)
$69.42
1.36
+2%
$5.62
-0.28
-4.75%
$180.65
-5.15
-2.77%
ViaSat Inc (VSAT)
$23.15
-0.36
-1.53%
$6.43
0.13
+2.06%
$30.18
0.27
+0.9%
$56.98
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Address

1001 Calle Amanecer, San Clemente, CA, United States, 92673